NO_LONGER_AVAILABLENCT04678479

Ganaxolone Expanded Access Program Compassionate Use

Studying CDKL5-deficiency disorder

Last synced from ClinicalTrials.gov May 8, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Marinus Pharmaceuticals
Principal Investigator: Paula Bokesch, MD, FAAP
Marinus Pharmaceuticals, Inc.
Intervention: Ganaxolone(drug)
Eligibility: 2 years · All sexes

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04678479 on ClinicalTrials.gov

Other trials for CDKL5-deficiency disorder

Additional recruiting or active studies for the same condition.

RECRUITINGNANCT06448663
Targeting the Gut to Improve Seizure Control in CDKL5 Deficiency Disorder (CDD)
University of Milan
ACTIVE NOT RECRUITINGNCT05373719
Observational Study in Patients With Cyclin-dependent Kinase-like 5 Deficiency Disorder
Loulou Foundation
ACTIVE NOT RECRUITINGPHASE3NCT05064878
A Study to Investigate the Efficacy and Safety of ZX008 in Subjects With CDKL5 Deficiency Disorder
Zogenix, Inc.
RECRUITINGNCT05558371
International CDKL5 Clinical Research Network
University of Colorado, Denver

See all trials for CDKL5-deficiency disorder →

← Back to all trials